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ABSTRACT
Objective: To develop methodological guidelines for pharmacoeconomic
evaluation (PE) submitted to the Belgian Drug Reimbursement Committee
as part of a drug reimbursement request.
Methods: In 2006, preliminary pharmacoeconomic guidelines were devel-
oped by a multidisciplinary research team. Their feasibility was tested and
discussed with all stakeholders. The guidelines were adapted and ﬁnalized
in 2008.
Results: The literature review should be transparent and reproducible. PE
should be performed from the perspective of the health-care payer, includ-
ing the governmental payer and the patient. The target population should
reﬂect the population identiﬁed for routine use. The comparator to be
considered in the evaluation is the treatment most likely to be replaced.
Cost-effectiveness and cost–utility analyses are accepted as reference case
techniques, under speciﬁc conditions. A ﬁnal end point—as opposed to a
surrogate end point—should be used in the incremental cost-effectiveness
ratio (ICER). For the calculation of quality-adjusted life-years (QALYs), a
generic quality-of-life measure should be used. PE should in principle
apply a lifetime horizon. Application of shorter time horizons requires
appropriate justiﬁcation. Uncertainty around the ICER should always be
assessed. Costs and outcomes should be discounted at 3% and 1.5%,
respectively.
Conclusion: The current guidelines are the result of a constructive col-
laboration between the Belgian Health Care Knowledge Centre, the
National Institute for Health and Disability Insurance and the pharma-
ceutical industry. A point of special attention is the accessibility of existing
Belgian resource use data for PE. As PE should serve Belgian health-care
policy, they should preferably be based on the best available data.
Keywords: guidelines, health policy, pharmacoeconomic evaluation,
reimbursement.
Introduction
Pharmaceutical products are reimbursed in Belgium on the basis
of their therapeutic value, and are categorized into three classes
accordingly. Class 1 drugs have a therapeutic added value com-
pared to existing therapeutic alternatives; class 2 drugs have a
comparable therapeutic value; and class 3 drugs are mainly
generics. Since 2002, a request for reimbursement of a pharma-
ceutical product of Class 1 by a pharmaceutical company has to
be accompanied by a pharmacoeconomic evaluation (PE). These
reimbursement requests are evaluated by the Drug Reimburse-
ment Committee (CTG/CRM), a division of the National Insti-
tute for Health and Disability Insurance (NIHDI). The decision
to list and reimburse and the level of reimbursement of a Class 1
drug is based on ﬁve criteria, as detailed in the Royal Decree [1]:
1. the therapeutic value, taking into account the efﬁcacy, effec-
tiveness, side effects, applicability and user-friendliness of
the product;
2. the market price of the drug and the requested reimburse-
ment price;
3. the clinical effectiveness and likely impact of the product,
taking into account therapeutic and social needs;
4. the budget impact for the National Health Insurance; and
5. the cost-effectiveness of the product from the perspective of
the National Health Insurance.
The deﬁnition of therapeutic value used in the Royal Decree is
broader than the notion of effectiveness or outcome, as frequently
used in clinical and economic literature. Besides morbidity, mor-
tality and health-related quality of life, it encompasses social and
practical components such as applicability of the product and
comfort of use. This larger deﬁnition has implications for the
assessment of the cost-effectiveness of a product. From published
data onClass 1 requests in the period 2002–2004, it appeared that
the claim of “added therapeutic value” was approved after evalu-
ation in only 48% of Class 1 submissions [2].
Based on an evaluation of the reimbursement report sub-
mitted by the pharmaceutical company, the Drug Reimburse-
ment Committee formulates a motivated advice for the Minister
of Health & Social Affairs about the appropriateness of reim-
bursement, the reimbursement rate, the conditions for reimburse-
ment and the class of the product.
The evaluation of the pharmacoeconomic analyses has been
hampered by the absence of formal guidelines for conducting
and reporting PE. A pilot assessment of 10 submitted ﬁles for
reimbursement requests revealed a large variability in metho-
dological quality and reporting formats, which leads to more
time consuming evaluation processes. The 10 ﬁles related to
10 different Class 1 products for which the reimbursement
request was submitted between 2002 and 2004. The aim of the
assessment was exploratory. The focus was on identifying the
perceived methodological problems in the submissions and
in the assessments made. Problem items appearing during the
assessment were noted in sequential order for each submission.
Methodological aspects were reviewed and classiﬁed according
to the QHES instrument [3], while for statistical problems
free text notes were taken of the type of problems encountered.
No scoring system of the submissions was performed as the
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research was exploratory in nature, aiming to identify the
strengths and weaknesses of the submissions rather than to
score the submissions. For the 10 reviewed pharmacoeconomic
studies, the major areas of concern were, in decreasing order of
occurrence:
1. methods and deﬁnitions of costs and cost measurement;
2. description of model validation, reliability and limitations,
and presentation of the model;
3. comparator choice;
4. deﬁnition and estimation of clinical effectiveness or efﬁcacy;
and
5. general shortcomings in uncertainty and sensitivity analysis.
These ﬁndings underscored the need for clear guidelines on
PE.
Objectives
The objective of this study was to develop methodological and
reporting guidelines for PE submitted to the Drug Reimburse-
ment Committee as part of a drug reimbursement request in
Belgium. The guidelines aim to increase the methodological
quality, transparency, and uniformity of the pharmacoeconomic
submissions. This will help to increase consistency across the
reimbursement ﬁles, both in the ﬁle submitted by applicants and
in the evaluation reports made by the Drug Reimbursement
Committee.
Methods
Existing guidelines from other countries were reviewed (Dutch
[4], French [5], Australian [6], and British [7] guidelines). Only
guidelines issued or updated after July 2003 were considered
because the ﬁeld of pharmacoeconomics is continually evolving
and regular updates are necessary. For most methodological
aspects, different approaches exist. To improve consistency in the
ﬁles, a “reference case” was presented, including the essential
elements for each PE together with the most appropriate metho-
dology given the objectives of the reimbursement committee, i.e.,
maximizing health gain within resource constraints. Additional
analyses using other approaches were allowed, but had to be
distinguished from the reference case analysis and justiﬁed.
The development of the guidelines was done in two phases.
Phase one consisted of the development of a set of draft guide-
lines. These provisional guidelines were developed by the Belgian
Health Care Knowledge Centre (KCE) in collaboration with the
NIHDI. The formal procedures for KCE studies were followed. A
group of external experts was invited to review draft documents
on a regular basis and give feedback during formal meetings. In
case no consensus was found on speciﬁc issues, the principal
investigators from KCE/NIHDI (authors of this paper) took the
ﬁnal decision. Therefore, the guidelines do not necessarily reﬂect
the personal opinions of the external experts. The ﬁnal document
was validated by three external validators that had not been
involved in the previous review process. They assessed the scien-
tiﬁc validity of the guidelines and were not allowed to impose
changes that purely reﬂected a personal opinion. The external
expert and validators group consisted of eight health economists
from Belgium and abroad, two pharmacists, one medical doctor
with training in health economics, and one statistician. Phase two
consisted of a practical implementation of these guidelines during
a 12-month period to test the guideline’s feasibility. Participation
in the pilot test was voluntary. One company submitted an adap-
tation according to the draft guidelines of an earlier submitted PE
of a product for which the reimbursement decision was already
taken. This approach was used to strictly separate the evaluation
of the guidelines from the procedural evaluation of the content of
the reimbursement request ﬁle. Based on the experience of this
company and the extensive feedback of about 20 pharmaceutical
companies through the representative organization of the phar-
maceutical industry in Belgium Pharma.be, the guidelines were
adapted and ﬁnalized [8]. The companies’ comments were some-
times a request for clariﬁcation, sometimes punctual and some-
times critical. One of the major concerns expressed by the
pharmaceutical companies is the lack of access to speciﬁc data
that are nevertheless available at the governmental level. This
concern could not be solved within the pharmacoeconomic
guidelines but the message was nevertheless transferred to the
Belgian policymakers. When the companies considered the inter-
pretation of a guideline in a speciﬁc situation unclear, the guide-
line was adapted to improve clarity and general applicability of
the guidelines. Concerns about legal issues, such as ownership of
data, or potential misuse of transferred data or models were
solved through discussion between the CTG/CRM and the
companies.
Pharmacoeconomic Guidelines
The reference case deﬁnes the elements of a PE and the recom-
mended methodology for each component (Table 1).
Guideline 1: Literature review
A thorough and systematic literature review of clinical effective-
ness and cost-effectiveness of the product is the starting point of
the PE, as its value crucially depends on the value of the evidence
it is based upon. This should be the best available up-to-date
evidence on the intervention and the comparator. Besides
published literature, an overview of ongoing studies should be
provided. Off-label medical treatments are not acceptable as
comparators in the formal economic evaluation because reim-
bursement is legally limited to the ofﬁcial indication in the
Summary of Product Characteristics (SPC). Nevertheless,
the evidence on their (cost-) effectiveness can be described in the
literature review. This increases transparency of the dossier, and
for the Drug Reimbursement Committee, the existence and
current use of an off-label used product can sometimes be a
consideration in the advice to the minister.
The basic principle of the literature search is transparency in
selection criteria and reproducibility of the search. The best
available up-to-date evidence can be found after the methodol-
ogy of systematic literature reviews, e.g., according to the guide-
lines of the Centre for Reviews and Dissemination [9].
The review should start with identiﬁcation of the review
questions. This includes speciﬁcation of the population, the inter-
vention, the comparator, the outcomes, and the study designs
selected. As for the outcomes, it is worth considering: 1) disease-
speciﬁc outcomes; 2) adverse events; 3) overall survival; and 4)
quality of life, for both the intervention and the comparator.
Databases searched should include at least MEDLINE,
Embase, the Cochrane Controlled Trials Register, the Cochrane
Database of Systematic reviews and the National Health Service
Centre for Reviews and Dissemination (NHS CRD) review data-
bases. The report of the literature review should include the
search strategy for each database, the study selection criteria,
selection procedures and results of the selection, the quality
assessment tools [10–13] and quality assessment results, and the
data extraction sheets. A synthesis of the evidence should be
provided.
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Table 1 Reference case methods
Component of
PE evaluation Reference case Guideline
Literature review • Description of the disease and the interventions studied
• Systematic review of the existing clinical and economic studies on the intervention: best available up-to-date evidence for clinical
effectiveness of the product and its cost-effectiveness relative to its comparator(s), ongoing studies should be mentioned
• Reproducible search strategy
• Transparent selection criteria and selection procedures
• Critical appraisal of the evidence
• Quality assessment of the evidence
• Data extraction sheets
• Clear and concise synthesis, substantiated with references
1
Perspective of
the evaluation
• Only direct health-care costs from the perspective of the health-care payer; this includes payments out of the government’s
health-care budget as well as patients’ copayments
• Health outcomes measured in patients and valued from a societal perspective
2
Target population • Consistent with the patient population deﬁned in registration documents
• Subgroup analyses if appropriate (statistical) justiﬁcation for subgroup analysis is provided
• Post hoc subgroup analyses only if costs between the subgroups are proven to be different based on appropriate statistical analyses.
(relative effectiveness must be assumed equal across subgroups in this case);
• Epidemiological data for Belgium presented for the entire target population and relevant subgroups.
3
Comparator • Comparison with either the treatment that is most likely to be replaced by the new treatment or, in case of add-on treatments, the
current treatment without the add-on product
• If most appropriate comparator unknown: recommended treatment according to the Belgian clinical guidelines
• Multiple comparators possible
• Medical and/or nonmedical treatment(s)
• No comparison with off-label used products in reference case analysis
• Justiﬁcation of the choice of the comparator(s)
• Indirect comparisons only allowed under speciﬁc conditions
4
Analytic technique • Cost-effectiveness analysis if improving life expectancy is the main objective of the treatment and the most important outcome
from the patient point of view or if there is a clearly identiﬁed dominant clinical outcome parameter that is relevant to the patient
(e.g., avoiding complications) and there are no other patient-relevant outcome parameters (e.g., side effects) expressed in different
units
• Cost–utility analysis if the treatment has an impact on health-related quality of life that is signiﬁcant to the patient or if there are
multiple patient-relevant clinical outcome parameters expressed in different units
• Cost–beneﬁt analyses are not accepted as a reference case
• Results expressed as incremental cost-effectiveness or cost–utility ratios with their associated distribution
• If a cost–utility ratio presented as reference case result, corresponding cost per life-year gained should also be presented
5
Study design • Pharmacoeconomic evaluations should always be based to some extent on data from RCTs or noninterventional studies comparing
the study product and a relevant comparator
• Economic evaluations based on active control studies are preferred
• If modeling is needed because clinical trials provide insufﬁcient information for the economic evaluation, the number of assumptions
not based on clinical evidence should be reduced to a minimum
6
Calculation of costs • The identiﬁcation, measurement and valuation of costs should be consistent with the perspective of the Belgian health-care payer.
Non–health-care costs or unrelated health-care costs should not be included in the reference case analysis.Validated sources should
be used for the unit costs.
• In the absence of market prices for speciﬁc resources, standardised proxies for unit costs can be used, unless the intervention is
expected to have a high impact on the value of the proxy. Data from private databases can be used provided that these databases
comply with legal requirements related to privacy issues.
• Where generic pharmaceutical products exist, the reference price for these products should be used in the pharmacoeconomic
evaluation, even if the generics are not frequently used in Belgium.
• For copayments, the general rule is to use the copayments paid by regularly insured patients falling outside any of the speciﬁc
categories that beneﬁt from increased reimbursement. Deviations from this rule should be justiﬁed.
7
Valuation of
outcomes
• Final end points, preferably clearly deﬁned outcome measures, for which there is little debate about the measurement methods
• Cost-effectiveness analyses: life years gained for chronic conditions and acute conditions with long term sequelae or a relevant short
term outcome for acute conditions with no long term consequences
• Cost–utility analyses: QALYs gained
• Life expectancy estimates based on Belgian age-speciﬁc life tables
• Health-related quality of life weights based on empirical data, obtained with a descriptive system for health status for which
corresponding preference values exist from the general public
• Quality of life weights derived with generic instrument
8
Time horizon • Chronic diseases and acute diseases with long-term sequelae: lifetime horizon
• Acute diseases without long term sequelae: shorter time horizon with appropriate justiﬁcation
9
Modeling • Applied if available data are insufﬁcient to allow a full assessment of the cost-effectiveness or cost–utility of a product
• Based as much as possible on data from clinical studies comparing the study medication and the comparator, on data from validated
databases and/or data from literature.
• Justiﬁcation for modeling
• Structural hypotheses, assumptions and sources of information presented in clear and transparent way.
• Model inputs and outputs consistent with existing data and have face validity.
• Primary data and original sources of information used to deﬁne the values of input parameters as well as the original computer
model are kept at the disposal of the Drug Reimbursement Committee.
10
Handling uncertainty • Uncertainty around cost-effectiveness/cost–utility estimates should always be analyzed
• Methodological uncertainty
• Data uncertainty
• For models, probabilistic sensitivity analyses
• Presentation of cost-effectiveness plane and cost-effectiveness acceptability curve or—for dominant interventions—the net
monetary beneﬁt function.
• Assessment of the most important contributors to the variability of the estimated incremental cost-effectiveness/cost–utility ratio.
11
Discount rate • Costs at 3%
• Beneﬁts at 1.5%
• Other scenarios can be presented to test sensitivity of results to discount rates applied
12
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If modeling is used for the PE, all (clinical) studies that served
as a basis for the modeling input parameters’ valuation should be
described, including their methodology, assumptions and results.
Relevance and appropriateness should be discussed. If unpub-
lished material is used in the economic evaluation, a sufﬁciently
detailed description of the material should be provided.
The external validity of study results included in the review
should be assessed [14], especially if these results are used in the
economic evaluation afterward. The external validity assessment
is mainly descriptive in nature.
Guideline 2: Perspective of the Evaluation
The health-care decision-maker is usually interested in the costs
of a treatment from the point of view of the health-care sector
and in the health gains for society. Health-care costs include costs
paid out of the health-care budget and patients’ copayments. To
be of interest to the decision-maker, the incremental costs should
reﬂect the incremental costs for the health-care payers, i.e., the
patients and the government who allocates the health-care
budget.
Outcomes included in the analysis should be relevant for the
patient population involved in the treatment and valued from a
societal perspective. If health-related quality of life is used as an
outcome measure, health states should be described by patients
but the values of health-related quality of life should be values
allocated to these states by the general public.
This recommendation does not mean that broader conse-
quences of a treatment cannot or will not be taken into account
in resource allocation decisions. The decision-maker may take
other consequences into account in determining the value of a
therapy: reductions in the absence from work; implications for
equity; organizational issues; population characteristics; budget
impact; etc. If these consequences are expected to be important
for a speciﬁc treatment, additional analyses can be presented but
these should be clearly distinguished from the reference case.
Guideline 3:Target Population
The target population described in the pharmacoeconomic ﬁle
should be consistent with the target population identiﬁed for
routine use of the product. The deﬁnition of the target popula-
tion for routine use of a product is not necessarily identical to the
population included in clinical trials, where selection criteria are
often very strict and not applicable to routine care (e.g., Phase I,
II, or III studies). If the implications of a product on the costs or
effects of treatment are proven to be different between subgroups
in the product registration ﬁle, subgroup analyses should be
performed in the PE. Even if subgroups are not analyzed in
clinical studies, however, there might still be room for subgroup
analyses in the economic evaluation, i.e., when the variables
affecting the cost-effectiveness are different from the variables
affecting the clinical efﬁcacy. Such analyses are post hoc sub-
group analyses. A number of conditions apply to post-hoc sub-
group analyses [8]. Care should be taken in using appropriate
statistical methods dealing with effect estimation in case of het-
erogeneity among subgroups [15] and not just multiply the
number of analyses which may generate spurious ﬁndings.
Guideline 4: Comparators
The drug should be compared with a treatment with proven
efﬁcacy (in RCTs) that is considered the recommended treatment
in daily practice in Belgium for the target indication. It is the
treatment that most prescribers would replace with the new
treatment if it becomes available and reimbursed. This can be a
medical or nonmedical treatment. Multiple comparators can be
considered if relevant in the Belgian context. Effective compara-
tors used in other countries but not (yet) in Belgium—although
potentially relevant for Belgium—should be described in the
literature review.
If it is not possible to identify the treatment most likely to be
replaced, the reference treatment, as deﬁned by Belgian clinical
guidelines, should be used. Guidelines or patterns of care from
other countries should be treated with caution, as they are not
necessarily relevant to Belgium.
The comparator can be another medical treatment, best sup-
portive care, watchful waiting or doing nothing. If the compara-
tor commonly used in clinical trials is no longer relevant, e.g.,
due to changes in prescription behavior or therapeutic insights
over time, indirect comparisons and/or modeling may be
required. Indirect comparisons are only acceptable if no single
trial of appropriate quality has been performed. Appropriate
statistical techniques must be used for indirect comparisons
[16–18].
If no direct comparisons between the standard treatment and
the study treatment are available and if indirect comparisons are
not possible, a PE cannot be performed.
Guideline 5: Analytic Technique
The report should specify whether a cost-effectiveness or cost–
utility analysis is used. Justiﬁcation for the choice of analytic
technique should be provided.
Cost-effectiveness analysis. In cost-effectiveness analyses, the
outcome should be expressed in terms of life years gained, unless
there are strong arguments to use another physical or clinical
outcome variable (e.g., in case of acute diseases without long-
term sequelae or in case of one major clinical outcome parameter
and a number of minor outcome parameters moving in the same
direction).
The incremental cost-effectiveness ratio (ICER) should be
presented unless the effectiveness of a drug is better and the costs
lower than the comparators’ (dominance), in which case the cost
savings and incremental effects are presented as separate values
rather than as a ratio.
Cost–utility analysis. A cost–utility analysis should be seen as a
complement to a cost-effectiveness analysis. If cost–utility analy-
sis is added to the reference case analysis, the report should also
contain the cost per life year gained to provide the most complete
information to the decision-maker.
Cost–utility analysis can be considered if the treatment has an
impact on health-related quality of life that is signiﬁcant to
patients or the treatment is associated with multiple clinical
outcomes that are expressed in different units (e.g., side effects vs.
survival).
Cost–utility is not relevant in all disease areas or treatment
situations. For instance, for drugs that cure short-term illnesses
(e.g., infections), quality of life is unlikely to be an issue. For very
serious infections, leading to a high short-term mortality rate but
little quality of life consequences in survivors (e.g., pneumonia),
it is more important to look at survival than to health-related
quality of life, and hence, cost-effectiveness analysis may be more
appropriate.
Cost-minimization analysis. Cost-minimization analyses are
used if the effects of two treatments are identical. Hence, cost-
minimization analysis can only be justiﬁed by proof of equal
outcome.
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Cost–beneﬁt analysis. Given the methodological difﬁculties and
controversies associated with the valuation of health outcomes in
monetary terms, cost–beneﬁt analysis is not acceptable as a
stand-alone reference case analysis, but may be presented as an
additional analysis to cost-effectiveness analysis or cost–utility
analysis to illustrate societal beneﬁts accruing from nonhealth
impacts.
Guideline 6: Study Design
Cost-effectiveness or cost–utility analysis can be performed
alongside a clinical study or can be based on a model. Each
design has its peculiarities and speciﬁc caveats. Analyses should
be explicit about the limitations of the design and should explain
the methods used to deal with these limitations.
Pharmacoeconomic evaluations alongside clinical studies. There
are basically two types of PE alongside clinical studies: piggy-
back studies, i.e., an evaluation alongside a randomized con-
trolled trial (RCT); and economic evaluations alongside
noninterventional studies.
The weaknesses of piggy-back studies are directly related to
the purpose of RCTs, where the primary objective is to evaluate
the efﬁcacy of a therapy. For economic evaluations, information
is needed on the effectiveness in routine practice. Other weak-
nesses of RCTs for the purpose of PE are potentially inappropri-
ate comparator, inadequate sample size, limited time horizon,
protocol-driven costs or outcomes, and inappropriate outcome
measures for economic evaluation purposes and patient selec-
tion. Moreover, when performed in other countries, the treat-
ment protocol of the RCT may be different from the protocol
that would be followed in Belgium. Some weaknesses, such as
the problem of protocol driven costs, can be overcome with
adequate methodology but others will require some extent of
modeling.
On the other hand, RCTs have the strongest design to dem-
onstrate differences in clinical efﬁcacy, which can be causally
linked to the treatment. Before reimbursement of a product, it is
often the only information available on the efﬁcacy of a product.
Piggy-back studies are useful if the weaknesses are made
explicit and whenever possible tackled in advance, either a priori
by including the economic evaluation in the study protocol of the
RCT or ex post by taking appropriate measures to tackle the
weaknesses.
Noninterventional studies avoid some of the weaknesses of
RCTs but may nevertheless be insufﬁcient to demonstrate long-
term cost-effectiveness of a product. Noninterventional studies
are especially useful to demonstrate the effectiveness (in contrast
to efﬁcacy), which is useful for the post-registration evaluation of
the real cost-effectiveness of the product after 1.5 to 3 years. At
the time of the reimbursement request, noninterventional studies
will usually not be available yet. As for interventional studies, the
design should take the speciﬁc elements needed for the economic
evaluation into account.
For PE alongside RCTs or noninterventional studies, original
data should be made available to the Drug Reimbursement Com-
mittee upon request.
Modeling. Even if a trial-based PE exists, some modeling is likely
to be needed (e.g., to extend the time horizon to longer time
spans or to model comparators, which have become more rel-
evant in practice since completion of the trial). Very often in the
analysis of an economic evaluation based on a clinical study,
certain assumptions will be made (e.g., assuming that the study
population and observed resource use are representative for
Belgium), which turns it de facto into a model. A separate guide-
line is devoted to modeling (see guideline 10).
Guideline 7: Calculation of Costs
Valuation of resource use in monetary units must be consistent
with the perspective of the analysis, i.e., the health-care payer’s.
For the health-care policymakers’ information, costs for the dif-
ferent categories of health-care payers should also be presented
separately, i.e., as costs borne by the different categories of
payers.
Cost categories. Table 2 speciﬁes the cost categories that should
be included or excluded from the cost analysis in the reference
case.
Only direct health-care costs should be included. If produc-
tivity losses, nonhealth-care costs, and/or unrelated health-care
costs are deemed important for a speciﬁc treatment, they may be
presented in a separate analysis.
Measurement of resource use. Measurement of resource use
should be done by means of observations or derived from litera-
ture. Observations offer the best guarantee for appropriateness of
the resource use estimates within the national context. Different
sources can be used to obtain observational data: clinical trials,
prospective observational studies, databases, and patient charts.
Expert panels should only be used as a complementary source
of information. The use of expert panel data is subject to speciﬁc
conditions: methods used to obtain resource use estimates from
experts should be transparent, questionnaires should be attached
to the report, and descriptive statistics—and in case of small
samples (<10 experts) individual responses—should be pre-
sented. Names and afﬁliations of experts should be disclosed.
If derived from literature or studies from other countries,
resource use estimates should be validated for Belgium. This
validation process must be described in the submitted ﬁle.
Ofﬁcial governmental data sources should be used whenever
possible [19]. Private databases can be used if they comply with
legal requirements about privacy. Each database has its weak-
nesses, such as for instance the cross-sectional nature of the data,
overestimation of the length of stay, imperfect registration, etc.
These weaknesses can generally not be remedied without major
assumptions. Therefore it is recommended to make explicit the
underlying assumptions and discuss their weaknesses and poten-
tial impact on the cost estimates in the text rather than to try to
solve them by means of ad hoc manipulations of the data.
Valuation of resource use. The principle of the cost analysis is
that costs are valued at opportunity costs. In practice, the oppor-
tunity costs will be approximated by market prices or some kind
of mechanism used for the reimbursement of procedures (e.g., the
Belgian per diem price). In the absence of a better alternative and
Table 2 Included and excluded costs in the reference case analysis
Health-care costs Nonhealth-care costs
Direct costs Included, e.g., health
services, medications,
hospitalizations . . .
Not included, e.g., travel
expenses to and from
hospital, informal care,
home care
Indirect costs Not included, e.g., health-care
costs in life years gained
(unrelated health-care
costs)
Not included, e.g.,
productivity losses
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for reasons of uniformity between analyses, it is suggested to use
these proxies in the reference case, knowing that these proxies do
not always reﬂect real opportunity costs. Alternative cost esti-
mates, e.g., based on microcosting approaches, can be presented
in alternative scenarios, and supported with arguments of why
the analyst thinks these alternative cost estimates are more
appropriate.
Where generic pharmaceutical products exist, the reference
price for these products should be used in the PE, even if the
generics are not frequently used in the target population in
Belgium. The rationale of this approach is that the limited use of
the generics is a policy issue that is outside the scope of the PE. The
aim of the PE is to assess the ICER relative to the appropriate
(cost-effective) comparator. If the comparator encompasses two
kinds of products with a different price but equal outcomes,
the least costly product should be used in the evaluation, as
this product is more cost-effective than its more expensive
counterpart.
Valuation of resource use by means of simple currency con-
version of values found in literature or in studies from other
countries is not acceptable. The values should reﬂect Belgian
prices/costs for each resource input rather than foreign prices
converted to euros.
Guideline 8: Estimation and Valuation of Outcomes
The valuation of outcomes depends on the analytic technique
used.
Effectiveness evaluation in cost-effectiveness analysis. In cost-
effectiveness analyses outcomes should be expressed in terms of
“number of life years gained”, unless there are strong arguments
in favor of another outcome parameter, e.g., in case of acute
diseases without long term sequelae. Age-speciﬁc life tables for
Belgium should be used to estimate life expectancy.
The estimated number of life years gained should consider the
impact of the treatment on all-causemortality in the reference case
analysis. Effectiveness estimates based on disease-speciﬁc mortal-
ity can be presented in complementary analyses. Unless the disease
has a major impact on overall mortality in the population exam-
ined, it is not necessary to correct all-causemortality ﬁgures for the
fact that they include disease-speciﬁc mortality [20]. All-cause
mortality should bemodeled nonparametrically based on life table
data. The functional form of the chosen disease-speciﬁc mortality
function should be explained and justiﬁed.
Utility assessment in cost–utility analysis. In cost–utility analy-
ses, the valuation methods for health-related quality of life
should be equal for all comparators. Data on survival and health-
related quality of life should be presented separately. QALYs
should not be weighted in the pharmacoeconomic analysis to
reﬂect distributional preferences of the general public as there is
too little evidence on the precise distributional preference func-
tion. This means that in submitted PE, a QALY is a QALY, no
matter to whom it accrues.
Quality of life assessment in speciﬁc health states, needed for
the calculation of QALYs, requires two steps: health state
description and health state valuation.
Health state description. Health states should be described on a
generic descriptive system such as the EQ-5D or SF-36. Health
state descriptions in similar patient populations in other coun-
tries may be used.
If it is thought that the generic instruments are insufﬁciently
sensitive to relevant changes in health in a speciﬁc disease,
additional (disease-speciﬁc) quality of life results can be
described in separate analyses.
The use of expert panels to describe patients’ health states is
only accepted if patients cannot describe their health state them-
selves (e.g., mentally ill patients, children, unconscious patients).
The reason for using expert panels for the description of health
states should always be justiﬁed.
Health state valuation. Health states should be valued on a 0
(= value for dead) to 1 (= value for perfect health) scale. Values
assigned to the health state descriptions should come from (a
representative sample of) the general public, preferably from
Belgium. Mapping valuations from other health-related quality
of life instruments (e.g., disease-speciﬁc instruments or another
generic instrument) to EQ-5D or SF-6D public preference values is
only allowed ifmapping functions are based on and validatedwith
empirical data. Hence, when mapping is done, the state-of-the art
methodology for mapping should be used.
If no original Belgian data are available and mapping is not
possible, generic health state descriptions and valuations from
other countries in the same patient population can be used,
provided that the source of the valuations is transparent and that
potential problems of transferability are discussed. If evidence
exists that preference values are stable across countries, this
should be described.
Disease-speciﬁc health state descriptions, obtained with a
sufﬁciently validated instrument for which references are pro-
vided, should also be valued by the general public. If no complete
valuation set for all health states that can be described with the
instrument can be inferred from a subset of valuations derived
from the general public, either Time Trade-Off (TTO) or Stan-
dard Gamble (SG) should be used for this valuation by the
general public. Selection of people from the general public, rep-
resentativeness and methods for surveying the subjects should be
described.
Health state values from different (clinical) studies should be
treated with utmost caution. Only if measured with the same
instrument and in a similar patient population are the values
comparable and can they be used in one and the same PE.
Consistency in methodology for the valuation of utilities of dif-
ferent health states in the PE should be pursued.
Guideline 9: Time Horizon
The time horizon of the economic evaluation should be in con-
cordance with the period over which the main differences in costs
and health consequences between the drug treatment and the
comparator are expected. Health consequences include intended
as well as unintended consequences (e.g., side effects).
Treatments for chronic diseases or acute diseases with long-
term sequelae mostly have consequences over a patient’s lifetime.
In these cases, a lifetime time horizon should be adopted for the
economic evaluation. Sometimes a shorter time horizon may be
justiﬁed, e.g., for very acute diseases with no differential mortal-
ity or long-term morbidity effect between treatment options and
with only short-term differential costs. If a shorter time horizon
is chosen, this should be substantiated with clear arguments. The
potential consequences of not including long term costs and
outcomes should in this case be discussed.
The expected appearance of an innovative drug in the near or
distant future is no argument for applying a shorter time horizon.
As long as the clinical effectiveness of these innovations is not
studied, it is impossible to perform a formal analysis of its likely
impact.
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Guideline 10: Modeling
Need for modeling. Models are used for different reasons: exten-
sion of time horizons, extrapolation of intermediate outcome
parameters to ﬁnal outcome parameters, simulation of effective-
ness as compared to efﬁcacy, consideration of externalities asso-
ciated with a treatment, indirect comparisons, translation of
foreign data to the Belgian context, etc. The strength of a mod-
eling approach is that pooled data, e.g., from meta-analyses of
different clinical trials, can be used for the economic evaluation.
The major weakness of models is that often major assumptions
have to be made (e.g., about the comparability of the data
derived from different sources, resource use in Belgium, etc). The
arguments for using a modeling approach should be set out
clearly and sources for hypotheses should be presented.
Modeling is optional. If good quality Belgian data from clini-
cal studies are available over a relevant time period, including all
appropriate outcome measures and reﬂecting the methodological
standards for trial-based PE (guideline 6), modeling is not
needed.
The guidelines for good modeling practices developed by the
modeling task force of ISPOR [20] should be followed.
Precision of model structure and hypotheses. The main principle
should be to keep the model as simple as possible. The more
complex the model, the more uncertain the results and the less
likely that one is able to populate the model with valid data.
All assumptions made in the model, be it for outcome assess-
ment, valuation of costs, and assessment of probabilities, should
be documented and justiﬁed. Preference is given to peer-reviewed
publications or primary data as source for the input parameters’
values. Expert panels are not allowed for the assessment of
probabilities or outcomes if data are available in literature. They
are of the lowest level of evidence. If no published evidence is
available and use of expert panels cannot be avoided, strict
methodological criteria apply. The use of expert panels is gener-
ally discouraged but should—if used—always be well justiﬁed.
All assumptions should be tested in the sensitivity analysis
and/or scenario analysis to test the robustness of the results.
For models that extrapolate to longer time periods, i.e., for
chronic conditions or treatments/diseases with long-term
sequelae, it is recommended to present different scenarios to
show the impact of different extrapolation approaches on the
results [21].
• The ﬁrst scenario assumes that the treatment effect disap-
pears immediately in the extrapolated phase (stop-and-drop
approach). This is the most conservative extrapolation
approach.
• The second scenario assumes that the incremental treatment
effect stays the same as during the observed phase.
• The third scenario assumes that the initial treatment effect
fades out in the long term.
The scenarios are all part of the reference case analysis
because the choice of an extrapolation approach is mainly a
judgment. The presentation of scenarios is the most transparent
option to show how robust the results are to the extrapolation
approach used. Each scenario should be accompanied by appro-
priate sensitivity analyses on uncertain parameters.
The original computer model should be put at the disposal of
the Drug Reimbursement Committee upon request. The choice of
the modeling software is free.
Calibration, face-validity and cross-validation of a model. The
results of the model should be logically consistent with real-life
observations and data (calibration) [20]. For example, if age-
speciﬁc incidences of a disease are used in a model, the total
incidence generated by the model should not considerably be
higher or lower than the observed incidence in the population,
unless the difference can be explained by differences in the popu-
lation structure. In other words, there must be a logical connec-
tion between inputs and outputs of a model.
The results of the model should be intuitively correct, that is,
the model should have face-validity. The model description
should be transparent enough to allow an explanation of the
differences with other models for the same interventions (cross-
validation) [20].
Guideline 11: Handling Uncertainty and Testing
Robustness of Results
Uncertainty is usually divided into three broad areas: 1) meth-
odological uncertainty coming from the analytical methods
chosen to perform the evaluation (e.g., discount rate or extrapo-
lation methods; this is usually handled by presenting results from
the reference case and a number of alternative scenarios); 2) data
uncertainty coming from variability in sample data (handled via
statistical analyses) or from uncertainty ranges chosen for non-
sample data (handled via sensitivity analyses); and 3) uncertain
generalizability of the study results to other populations and/or
other contexts (handled via descriptive external validity assess-
ment). Each of these three areas of uncertainty should be speciﬁ-
cally addressed in the sensitivity analysis [22].
In case of modeling, probabilistic sensitivity analyses should
be performed on all uncertain parameters in a model, e.g., by
means of Monte Carlo simulation. Distributions used for the
uncertain modeling parameters should be justiﬁed. The central
estimate of the ICER results directly from the probabilistic sen-
sitivity analysis as the mean of the simulated ICERs. This is not
necessarily equal or close to the ratio of the mean incremental
cost and mean incremental effect, which is the deterministic
version of the ICER. A deterministic ICER can be presented if the
Monte Carlo simulations fall in different quadrants of the cost-
effectiveness plane.
In addition to probabilistic sensitivity analyses, a scenario or
univariable sensitivity analysis could be performed on modeling
parameters that are decisive for the cost-effectiveness ratio such
as the price of the product or the discount rate for costs and
outcomes. For each scenario, a probabilistic sensitivity analysis
can be easily performed, and hence, results can be presented with
their 95% credibility interval. Values and distributions of other
parameters can be kept as in the reference case analysis for these
scenarios. There is no need to present all possible combinations
of all scenarios. The applicant is free to present additional
univariable sensitivity or scenario analyses if these are deemed
relevant. Appropriate justiﬁcation of the additional analyses
should be provided.
In the case of observed cost and effects data in a trial based
pharmacoeconomic study, state-of-the-art methods should be
used for the estimation of the conﬁdence interval around the
incremental cost-effectiveness ratio (e.g., bootstrapping).
The cost-effectiveness plane, with the results of the Monte
Carlo simulations or bootstrapping, should be presented, both
for the cost per QALY gained and for the cost per life year
gained. In addition, a cost-effectiveness acceptability curve
should be presented to show the probability that the treatment is
cost-effective, given varying threshold values for the ICER.
If the results of the probabilistic sensitivity analysis shows a
negative lower bound for the ICER, the incremental costs (or
savings) and incremental effects (or harms) should be reported
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separately for the lower bound of the 95% credibility interval,
the point estimate and the upper bound of the 95% credibility
interval. In addition, the percentage of the simulations where a
negative ICER was found should be reported (if the simulated
results fall in different quadrants of the cost-effectiveness plane,
a separate percentage for each quadrant should be reported).
Guideline 12: Discount Rate
Incremental cost-effectiveness ratios should be presented in
present values. This means that future costs and beneﬁts should
be discounted to reﬂect the lower value given to future costs and
beneﬁts. The “right” choice for the discount rate of costs and
beneﬁts is still a matter of debate [23–26]. The choice of the
discount rate for costs is based on the return on risk-free gov-
ernment bonds, currently about 3% in Belgium. The choice of
the discount rate for outcomes is based on the expected relative
changes in budgets and productivity over time. This is highly
uncertain. Therefore, the discount rate for outcomes is uncertain.
Awaiting further evidence on the most likely discount rate for
outcomes in Belgium, the guidelines currently recommend a rate
of 1.5% for discounting outcomes in the reference case analysis.
Apart from the reference case analysis with a 3% discount rate
for costs and 1.5% for effects, the applicant can choose to present
alternative scenarios to allow the decision-maker to judge the
relative importance of using different discount rates for the ﬁnal
result. Given the prevailing advice for the base-case analysis in
many pharmacoeconomic guidelines of other countries, a 3%
discount rate for both costs and beneﬁts can be considered. If
comparison between evaluations is possible and useful, the 3%
discount rate scenario for both costs and beneﬁts could be
presented.
Discussion
These methodological guidelines are developed as a tool to make
pharmacoeconomic submissions and evaluations in Belgium
more transparent and consistent but could actually serve a much
broader goal, being to make all economic evaluations of health
interventions more consistent and therefore more useful for
health-care policy decisions, including evaluations not conducted
to request drug reimbursement. These guidelines are also
expected to enhance the power to differentiate between medicinal
products which are “value for money” from those who are not.
The ultimate decision to reimburse or not to reimburse a drug
is multifactorial. It will depend on the quality of the submitted
document and the therapeutic value of the drug, and also on
other aspects that may not be considered explicitly in the sub-
mission but may nevertheless be important from a health policy
perspective, e.g., equity implications, severity of disease, patient
characteristics, budget impact, and organizational issues. As
such, the PE will be but one input in the decision-making process.
The discussion about the appropriate threshold value against
which ICERs of interventions should be compared, was consid-
ered an issue requiring additional research and discussion with
policymakers. The project is ongoing at KCE. A report will be
available by the end of 2008.
Based on the assessment of the ﬁle submitted for evaluation in
the context of the pilot phase of the preliminary guidelines and
extensive discussions with the representatives of the pharmaceu-
tical industry, a number of issues were raised and some common
pitfalls in economic evaluation ﬁles, such as selective presenta-
tion of evidence on effectiveness, underreporting of uncertainty
ranges for input parameters of models, were highlighted.
Data requirements for good economic evaluations are high.
However, pharmaceutical companies are often faced with no or
very limited access to good quality Belgian data, although such
data are available. This often hampers good quality and relevant
PE. In Belgium, a lot of useful data for PE are routinely collected
with public resources. For example, data on patients’ copay-
ments for nondrug interventions are available but not accessible
for companies, while these are needed in the calculation of the
costs from the perspective of the health-care payer, including the
health insurance and the patients. As long as access to routinely
collected resource use data is limited for PE that are to inform
healthcare policymakers, the quality of the evaluations, and ulti-
mately the decisions, will remain suboptimal. With the expected
increasing importance of cost-effectiveness considerations in
reimbursement decisions, facilitating access to essential public
resource use data to the people performing economic evaluations
is indispensable, including the companies, their subcontractors
for the economic evaluation and other experts performing health
economic evaluations that serve resource allocation decisions.
With increasing access to essential data for PE, guidelines can
be revised to become more speciﬁc and precise, thereby in-
creasing even more the relevance of the evaluations for Belgian
policymakers.
Lack of access to relevant Belgian data revealed the question
from the pharmaceutical companies “to what extent the use of
data from other countries would be acceptable.” While the pre-
liminary guidelines contained a separate guideline on the assess-
ment of the transferability of data used in the PE, the ﬁnal
guidelines included the transferability issue in each separate
guideline where relevant. The idea was that it is not required to
write a separate chapter in the drug reimbursement request on
the transferability of each element “borrowed” from another
country, but that the data sources and relevance of the data for
Belgium should be discussed when they are presented. The
ISPOR Good Research Practices on Economic Data Transferabil-
ity Task Force recently reviewed what national pharmacoeco-
nomic guidelines say about transferability and recommended
good research practices for dealing with aspects of transferability
[27]. The Belgian guidelines are in line with these recommenda-
tions, although they are not as speciﬁc as the Task Force’s on
speciﬁc items and are slightly different on some items. The major
emphasis in the Belgian guidelines is on transparency in method-
ology and sources used and justiﬁcation of choices. This includes
the choice of using data or models from other countries. The
basic principle is that the PE should be relevant for Belgium. The
guidelines are not speciﬁc about the methodology that should be
used to assess transferability of data from other countries, but
state that presumed transferability should always be justiﬁed
with clear arguments. This might include a detailed presentation
of the methods that were used to obtain the data in the other
countries and, if data or models have been modiﬁed to better
reﬂect the Belgian situation, the methodology that was followed
to do this. The guidelines are more tolerant toward the use of
clinical effectiveness data from other countries (e.g., relative risk
reduction) than for the use of cost data, which is in line with the
ISPOR Task Force recommendation. For the assessment of base-
line risk, existing sources should be used as far as they are
available and accessible.
In contrast to the Task Force, the Belgian pharmacoeconomic
guidelines are silent about the use of individual patient data from
multinational studies that included Belgium. While the guidelines
do state that empirical data are the preferred source of inputs for
the PE, implicitly including multinational studies, they do not
give speciﬁc guidance about how to obtain the best Belgian data
from these studies in cases where Belgium participated in the
study. That this question did not come up during the discussions
with the industry might be related to the fact that Belgium is, as
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suggested by the Task Force, a relatively small market, and
therefore, the number of Belgian patients included in these
studies would be relatively limited.
For drug reimbursement decisions, it is preferred that the
outcome data used in PE reﬂect the interventions’ effectiveness in
daily practice (i.e., effectiveness in contrast to efﬁcacy). Effective-
ness is evaluated by means of a noninterventional study.
However, it is clear that at the time of reimbursement request
such evidence is rarely available, as the product is not (yet)
widely used. Therefore, if companies would already plan the
organization of an effectiveness evaluation study and the collec-
tion of economic data alongside this study at the time of submis-
sion of the registration request, this kind of evidence may be
available at the time of the initial reimbursement request. This
would strengthen the PE. If still insufﬁcient data are available
from the study at the time of the initial submission, more data
will nevertheless be available at the time of the revision 1.5 to 3
years after the initial submission. Especially for products with
potentially long-term effects, which would not be observed in a
one- or two-year clinical study, it may be particularly interesting
to start organizing an active control study at the time of regis-
tration of a product.
Conclusions
The guidelines encompass today’s “state of the art” methodolo-
gies for PE. As this ﬁeld of expertise is continuously evolving,
these guidelines will have to be updated regularly to ensure that
most appropriate designs and methods are used in Belgian PEs.
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